Secarna Pharmaceuticals is redefining the discovery and development of oligonucleotide therapeutics to address hard-to-treat disorders. The Company is planning to raise a Series A to advance its lead oncology asset, SECN-15, into Phase 1/2. Secarna is supported by global partnerships that validate their expertise and accelerate development.
https://european-biotechnology.com/wp-content/uploads/2026/06/Seite-39_Secarna_Konstantin-Petropoulos.jpg540960Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-06-08 11:18:562026-06-08 11:18:56Next-gen oligonucleotides to transform patient care
Swiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader being developed for B-cell malignancies and potentially for immunology and neurology indications.
Swiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.
https://european-biotechnology.com/wp-content/uploads/2026/06/nigel-hoare-fKnwHfCWyWU-unsplash-scaled.jpg14402560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-06-05 16:45:252026-06-05 16:45:25ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm
Dr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
The announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned investments in Germany into question, citing the country’s healthcare policy framework.
https://european-biotechnology.com/wp-content/uploads/2026/06/davidcohen-R4VXMRFVcE4-unsplash-scaled.jpg19522560Georg Kääb/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngGeorg Kääb2026-06-05 15:45:382026-06-05 15:45:38Lilly and Boehringer pause $2bn German investments over planned drug-spending curbs
Barcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.
https://european-biotechnology.com/wp-content/uploads/2026/06/kristina-flour-BcjdbyKWquw-unsplash-scaled.jpg16382560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-06-04 10:42:152026-06-04 10:42:15Ona Therapeutics bags $86.6m Series B for stealth ADC push
Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.
https://european-biotechnology.com/wp-content/uploads/2026/06/curated-lifestyle-e_7SkKmT3yQ-unsplash-scaled.jpg17082560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-06-03 09:56:532026-06-03 09:56:53Ingenix raises €13m to scale AI drug development engine
3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.
https://european-biotechnology.com/wp-content/uploads/2026/06/image.png432768a.macht/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pnga.macht2026-06-02 23:34:322026-06-02 23:36:053PBIOVIAN expands its mammalian capacity with an additional 2,000 L bioreactor
London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.
https://european-biotechnology.com/wp-content/uploads/2026/06/olav-ahrens-rotne-jvBXiynINGE-unsplash-scaled.jpg17072560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-06-02 14:43:162026-06-02 17:12:47IMU Biosciences secures US$53m to decode the immune system
Parisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.
Next-gen oligonucleotides to transform patient care
Sponsored PublicationsSecarna Pharmaceuticals is redefining the discovery and development of oligonucleotide therapeutics to address hard-to-treat disorders. The Company is planning to raise a Series A to advance its lead oncology asset, SECN-15, into Phase 1/2. Secarna is supported by global partnerships that validate their expertise and accelerate development.
Roche bets on BTK degradation in $2.3bn Nurix deal
Latest NewsSwiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader being developed for B-cell malignancies and potentially for immunology and neurology indications.
ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm
Latest NewsSwiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.
Biotechnology expert joins CDMO
AppointmentsDr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
Lilly and Boehringer pause $2bn German investments over planned drug-spending curbs
Latest NewsThe announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned investments in Germany into question, citing the country’s healthcare policy framework.
Ona Therapeutics bags $86.6m Series B for stealth ADC push
Latest NewsBarcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.
Ingenix raises €13m to scale AI drug development engine
Latest NewsWarsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.
3PBIOVIAN expands its mammalian capacity with an additional 2,000 L bioreactor
slider, Sponsored Publications3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.
IMU Biosciences secures US$53m to decode the immune system
Latest NewsLondon-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.
Abivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-off
Latest NewsParisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.